Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 8:360:k698.
doi: 10.1136/bmj.k698.

Key design considerations for adaptive clinical trials: a primer for clinicians

Affiliations

Key design considerations for adaptive clinical trials: a primer for clinicians

Kristian Thorlund et al. BMJ. .

Abstract

This article reviews important considerations for researchers who are designing adaptive clinical trials. These differ from conventional clinical trials because they allow and even enforce continual modifications to key components of trial design while data are being collected. This innovative approach has the potential to reduce resource use, decrease time to trial completion, limit allocation of participants to inferior interventions, and improve the likelihood that trial results will be scientifically or clinically relevant. Adaptive designs have mostly been used in trials evaluating drugs, but their use is spreading. The US Food and Drug Administration recently issued guidance on adaptive trial designs, which highlighted general principles and different types of adaptive clinical trials but did not provide concrete guidance about important considerations in designing such trials. Decisions to adapt a trial are not arbitrary; they are based on decision rules that have been rigorously examined via statistical simulations before the first trial participant is enrolled. The authors review important characteristics of adaptive trials and common types of study modifications and provide a practical guide, illustrated with a case study, to aid investigators who are planning an adaptive clinical trial

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.

Figures

Fig 1
Fig 1
Common types of adaptive trials. Sample size reassessment: if interim analysis shows worse results than expected, the sample size can be reassessed and increased to ensure that the trial is adequately powered. Response adaptive randomisation: if interim analysis shows promising results for a treatment, the allocation ratio can be modified to favours enrolment to that treatment. Adaptive enrichment: if interim analysis shows that a treatment has more promising results in one subgroup of patients, the study eligibility criteria can be modified to investigate the efficacy of the intervention in the that subgroup, with a sample size reassessment to ensure a sufficient sample size. SSR=sample size reassessment
Fig 2
Fig 2
Adaptive design planning process
Fig 3
Fig 3
Case study of a dose-response adaptive trial. VAS=visual analogue scale

References

    1. European Medicines Agency. Adaptive pathways 2017 http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/gen....
    1. United States Food and Drug Administration. Adaptive designs for medical device clinical studies., 2016. https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance...
    1. Guyatt GH, Mills EJ, Elbourne D. In the era of systematic reviews, does the size of an individual trial still matter. PLoS Med 2008;5:e4. 10.1371/journal.pmed.0050004 - DOI - PMC - PubMed
    1. Bauer P, Koenig F. The reassessment of trial perspectives from interim data--a critical view. Stat Med 2006;25:23-36. 10.1002/sim.2180 - DOI - PubMed
    1. Ning J, Huang X. Response-adaptive randomization for clinical trials with adjustment for covariate imbalance. Stat Med 2010;29:1761-8. 10.1002/sim.3978 - DOI - PMC - PubMed

Publication types

MeSH terms